417O Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)

Authors :: Marco Angelo Burgio
David R. Spigel
Everett E. Vokes
Christopher T. Harbison
Ang Li
Neal Ready
Enriqueta Felip
Scott N. Gettinger
Martin Reck
Martin Steins
Hossein Borghaei
Julie R. Brahmer
Fabrice Barlesi
Luis Paz-Ares
Leora Horn
Esther Holgado
Jérôme Fayette
M.J. Kohlhäufl
Laura Q.M. Chow
Friedrich Graf Finckenstein
Source :: Annals of Oncology. 26:ix125
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Checkmate
non-small cell lung cancer (NSCLC)
Hematology
medicine.disease
law.invention
Docetaxel
Patient Self-Report
Randomized controlled trial
law
Non squamous
Internal medicine
Medicine
Nivolumab
business
medicine.drug

Tools